# US 2019/0316183 A1 · Fast diagnosis and personalized treatments for acne

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316183 A1
- Document ID: US20190316183A1
- Status: Published application
- Kind: A1
- Application number: 16/390,575
- Filed: 2019-04-22
- Published: 2019-10-17
- Earliest claimed: 2012-03-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Huiying Li; Shuta Tomida; Robert L. Modlin; Jeffery F. Miller; Sorel T. Fitz-Gibbon
- Web page: https://patentgrep.com/patent/US20190316183A1

## CPC

- C12Q 1/689: for bacteria
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/05: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
- A61P 17/10: Anti-acne agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/701: {Specific hybridization probes}
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

## Claims

### Claim at position 1

1-46. (canceled)

### Claim 47

A method of treating a skin condition in a subject in need thereof, the method comprising administering to the subject a composition comprising a P. acnes strain associated with healthy skin.

### Claim 48 (depends on 47)

The method of claim 47, wherein the skin condition is acne.

### Claim 49 (depends on 47)

The method of claim 47, wherein the composition is formulated in a topical cream or solution.

### Claim 50 (depends on 47)

The method of claim 47, wherein the composition is formulated in a cosmetic product.

### Claim 51 (depends on 47)

The method of claim 47, wherein the P. acnes strain associated with healthy skin does not have a ribotype comprising RT4, RT5, RT7, RT8, RT9 or RT10.

### Claim 52 (depends on 47)

The method of claim 47, wherein the P. acnes strain lacks a plasmid having SEQ ID NO: 31.

### Claim 53 (depends on 47)

The method of claim 47, wherein the P. acnes strain lacks a locus having SEQ ID NO: 29.

### Claim 54 (depends on 47)

The method of claim 47, wherein the P. acnes strain lacks a locus having SEQ ID NO: 30.

### Claim 55 (depends on 47)

The method of claim 47, wherein the P. acnes is characterized as associated with healthy skin based on its 16S rDNA.

### Claim 56 (depends on 47)

The method of claim 47, wherein treatment comprises prevention of acne.

### Claim 57 (depends on 47)

The method of claim 47, further comprising treating the subject with an active ingredient targeting a P. acnes associated with acne.

### Claim 58 (depends on 47)

The method of claim 47, wherein the P. acnes strain comprises CRISPR.

### Claim 59

A composition comprising a topical cream and a P. acnes strain associated with healthy skin.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the P. acnes strain associated with healthy skin does not have a ribotype comprising RT4, RT5, RT7, RT8, RT9 or RT10.

### Claim 61 (depends on 59)

The composition of claim 59, wherein the P. acnes strain lacks a plasmid having SEQ ID NO: 31.

### Claim 62 (depends on 59)

The composition of claim 59, wherein the P. acnes strain lacks a locus having SEQ ID NO: 29.

### Claim 63 (depends on 59)

The composition of claim 59, wherein the P. acnes strain lacks a locus having SEQ ID NO: 30.

### Claim 64 (depends on 59)

The composition of claim 59, wherein the P. acnes is characterized as associated with healthy skin based on its 16S rDNA.

### Claim 65 (depends on 59)

The composition of claim 59, further comprising an active ingredient targeting a P. acnes associated with acne.

### Claim 66 (depends on 59)

The composition of claim 59, wherein the P. acnes comprises CRISPR.
